KKR Sells 5M BridgeBio Shares at $78 in $390M Secondary Offering
BBIO sits 71% above its 52-week low of $46.81 on light trading volume (0.4× avg).
Summary
KKR is selling 5 million BridgeBio shares at $78.00 each in a $390 million secondary offering, reducing its stake from 7.3% to 4.7%. The company receives no proceeds.
Key Events · Financing and Capital Events · BBIO
-
KKR Sells 5M Shares
KKR Genetic Disorder L.P. is selling 5,000,000 shares at $78.00 per share, totaling $390 million. The company receives no proceeds.
-
Stake Drops Below 5%
KKR's beneficial ownership falls from 14,232,739 shares (7.3%) to 9,232,739 shares (4.7%), crossing below the 5% reporting threshold.
-
Priced at 2.3% Discount
The offering price of $78.00 is 2.3% below the last close of $79.83, indicating a modest discount to market.
-
Underwriters and Conflict
William Blair, Goldman Sachs, and KKR Capital Markets are underwriting. KKR Capital Markets has a conflict of interest under FINRA Rule 5121 because KKR affiliates are selling stockholders.
Analysis · BBIO · Life Sciences
KKR Genetic Disorder L.P. is selling 5 million shares of BridgeBio at $78.00 per share, a 2.3% discount to the last close of $79.83. The company receives no proceeds — this is a secondary sale by an existing holder. KKR's stake drops from 7.3% to 4.7%, crossing below the 5% reporting threshold. The offering is priced near market, suggesting orderly distribution rather than distress, but the overhang of a large block sale can pressure the stock in the near term.
At the time of this filing, BBIO was trading at $79.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $46.81 to $93.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.